Navigation Links
St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity
Date:5/12/2008

ITAMs are components of the CD3 adaptor proteins that attach to the T cell receptor and help transmit the control signals from the T cell receptor into the cell.

"The ITAMs we studied are little molecular tags inside the cell by which the T cell receptor communicates to the rest of the cell," Vignali said. "The mystery we wanted to address was why the T cell receptor needs 10 ITAMs to do its job. Why not just have a simple on/off switch?"

To explore the role of multiple ITAMs, Jeff Holst, Ph.D., the paper's first author and a St. Jude postdoctoral scientist, used a technique developed in the Vignali lab to produce mice whose T cells have variations in the number and type of functional ITAMs. The technique involved using a virus as a genetic cargo-carrier to transport genes for different combinations of normal and mutant non-functional ITAMs into the mouse cells.

The researchers found that reducing the number of normal ITAMs caused the mice to develop autoimmune disease. However, the investigators also found that some mice with fewer than normal functional ITAMs did not become sick with autoimmune disease. Vignali said this finding suggests that it is not just the number of ITAMs, but also their type that may influence T cell function.

"We theorized that there were two possibilities why the immune system needs so many ITAMs," he said. "One is that the requirement was purely quantitative, and that the ITAMs were there for signal amplification. The second possibility is that different ITAMs do slightly different things -- they do have slightly different structures, so maybe they bind to some signaling molecules better than others; and their positions in the T cell receptor are different. So, while our primary observation is that quantity is more important than ITAM type, we also found that type has some influence."

The researchers' analyses of the immune systems of the altered mice indicated that reducing the number of norm
'/>"/>

SOURCE St. Jude Children's Research Hospital
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile
2. New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR
3. New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery
4. New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
5. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
6. Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals
7. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
8. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
9. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
10. Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents
11. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...e/-- ChemoCentryx,Inc.,announcedtodaythatPhaseII/...ctiveRandomizedOralTherapyEvaluationinCrohn,sdisea...oderate-to-severeCrohn,sdiseasedemonstratedclinica...e.Thestudydemonstratedevidenceofclinicalefficacyin...ecreaseintheCrohn,sDiseaseActivityIndex(CDAI)inpat...
(Date:11/24/2009)..., WHAT:RomHoubens,aBelgianmanthoughttohavebeeninco...lyconsciousandawakeduringthattimeandwasthesubjecto...turedinthesegmenttoillustratehowpeoplewithLocked-i... ,, WHEN:GoodMorningAmerica-- Tuesday,November2..., WHO:RomHoubenswasanengineeringstudentin1986when...
(Date:11/24/2009)...Call/--QuestDiagnosticsIncorporated(NYSE: DGX ),th...tionandservices,announcedthatitisscheduledtospeaka...wYorkCity.ThepresentationisscheduledforWednesday,D...econference,thecompanywillreaffirmits2009guidancef...ceed18%ofrevenues,anddilutedearningspersharefromco...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 1 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 2 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 3 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 4 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 5 2416 Million in Federal Stimulus Funding Establishes Seattle as a Hub of Comparative Effectiveness Research In Cancer 58883 6AlphaHelix Presents AmpXpress 28TM 29 at the BIOTECHNICA Show 14356 1AlphaHelix Presents AmpXpress 28TM 29 at the BIOTECHNICA Show 14356 2US HIFU Appoints Arie Belldegrun M D to Board of Directors 5229 1US HIFU Appoints Arie Belldegrun M D to Board of Directors 5229 2US HIFU Appoints Arie Belldegrun M D to Board of Directors 5229 3
...orporation (Nasdaq:,DNDN) today will present a sum...uleucel-T), an investigational active cellular imm...um in New York City. The presentation, which,integ...s the safety,profile, immune response and clinical...sitive cancer who have failed standard therapy., ...
...Pharmaceuticals,Inc. (Nasdaq: VIAP ), a biotechno...ds for the treatment of cardiovascular disease, an...and webcast to discuss results of the,VIA-2291 Pha...arterectomy,(CEA) trials presented at the American...on Sunday, November 9. The conference call and web...
Other Medicine Technology:Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium 2Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium 3Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium 4VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA 2
(Date:11/25/2009)...swire/--WhenmostpeopleheartheacronymTMJ,theythinko...hehelptheyneed.TMJstandsfortheTemporal-MandibularJ...swithyourskull(temporalbone). ,, Themostcommons...ing,clickingorpoppingofthejaw.Butmanyothersymptoms...atigue,sleepdisturbances,irritability,alossinfocus...
(Date:11/25/2009)...leMedicalInc.,aleadingmanufacturerofbreastMRIcoils...wleadingedgeclinicalapplicationsonitsAegis(TM)medi...SocietyofNorthAmerica(RSNA)annualmeetinginChicago,...leveragetheuniquehighqualityimagesgeneratedbySenti...eimagingmodalitiesformulti-parametricassessment. ,...
(Date:11/25/2009)...eBayAreaAirQualityManagementDistrictisissuingthese... forThursday,November26,2009whichbansburningwood...rsandoutdoors. ,, "Cold,stillweatherwillcontrib...t,executiveofficeroftheAirDistrict."We,reaskingBay...fellowcommunitymembersthisThanksgiving,andnottobur...
(Date:11/25/2009)... a collaboration between UCLA engineers and physic... million Americans who suffer from peripheral arte...he arteries, peripheral arterial disease, or PAD, ...arteries reduce blood flow to the limbs. The condi..., heart attack and stroke, and its progression can...
(Date:11/25/2009)...eatment clinics to resume Monday, Nov. 30 , ...2009 -- Centegra Health System is continuing to of...four Centegra Primary Care (CPC) vaccination clini...The clinics are at CPC sites in Huntley, Woodstock...lows: ,   From 4:30 to 7:30 p.m. Tuesd...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4
...NTO, Calif., Feb. 20 CUREXO Technology Corporatio... image-directed robotic products for orthopaedic a...otic system, announced today that it has submitted... Surgical System for Total Knee Arthroplasty (TKA)...
... Calif., Feb. 25 Already a leader in the High T... Brand Intelligence software, is now offering its ...panies. , , Stu Clifton, New Momentum CEO, repo...twice the pace of legitimate pharmaceuticals -- an...
...ip anchor made from bioabsorbable Hydroxyapatite (...ew,s (NYSE: SNN ; LSE: SN) Endoscopy Division ha...or repair in the hip and shoulder. The device is s...rm an estimated 15,000 labral repair procedures in...
...gests jobs such as baby-sitting, lawn mowing could...lthDay News) -- A new study suggests it,s possible...juvenile delinquent. , Researchers found that fift...gs don,t prove that overwork directly leads to tro...
...turing efforts include the re-alignment of shared ...lishment of Pharmaceutical Governance and Medical ...nd PRINCETON, N.J., Feb. 25 Otsuka America Pharma...he North American pharmaceutical organizations, on...
... Feb. 25 The patent expiry of blockbuster molecul...confronting intense competition from generics. CEO...ative approaches to maintain the growth of their o...ter drugs represents a potential strategy that can...
Other Medicine News:Health News:CUREXO Technology Corporation Announces 510(k) Submission to FDA for Total Knee Arthroplasty Application 2Health News:New Momentum Launches Anti-Counterfeiting Software for Pharmaceutical Companies 2Health News:Smith & Nephew Endoscopy's OSTEORAPTOR(TM) Anchor Provides Bioabsorbable Solution for Labral Tears in the Hip and Shoulder 2Health News:Smith & Nephew Endoscopy's OSTEORAPTOR(TM) Anchor Provides Bioabsorbable Solution for Labral Tears in the Hip and Shoulder 3Health News:Smith & Nephew Endoscopy's OSTEORAPTOR(TM) Anchor Provides Bioabsorbable Solution for Labral Tears in the Hip and Shoulder 4Health News:Work May Not Be Best for Young Kids 2Health News:Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. Announce Restructuring Changes Aimed at Growing Otsuka's Pharmaceutical Business Worldwide 2Health News:Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. Announce Restructuring Changes Aimed at Growing Otsuka's Pharmaceutical Business Worldwide 3Health News:Market for Niche Blockbusters Promises an Attractive Future for Large Pharmaceutical Companies, Indicates Frost & Sullivan 2Health News:Market for Niche Blockbusters Promises an Attractive Future for Large Pharmaceutical Companies, Indicates Frost & Sullivan 3Health News:Market for Niche Blockbusters Promises an Attractive Future for Large Pharmaceutical Companies, Indicates Frost & Sullivan 4
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
Medicine Products: